Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 11/2010

01-11-2010 | Original Article

A novel SR protein binding site in a cis-regulatory element of HIV-1

Authors: Ornpreya Suptawiwat, Chompunuch Boonarkart, Prasert Auewarakul

Published in: Archives of Virology | Issue 11/2010

Login to get access

Abstract

We have previously described a cis enhancing sequence (CES) in the gp41 region of the HIV-1 env gene. It could enhance HIV-1 Gag expression via both rev-dependent and CTE (constitutive transport element)-dependent pathways. We identified a functionally important and conserved region in the CES that contained a predicted binding sequence for an SR protein, ASF/SF2. We show here that ASF/SF2 bound to this sequence in an electrophoretic mobility shift assay and that the putative ASF/SF2-binding sequence was required for the enhancement of Gag expression by CES and might play a role in HIV-1 posttranscriptional regulation.
Literature
1.
Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31:3568–3571CrossRefPubMed
2.
Damgaard CK, Kahns S, Lykke-Andersen S, Nielsen AL, Jensen TH, Kjems J (2008) A 5′ splice site enhances the recruitment of basal transcription initiation factors in vivo. Mol Cell 29:271–278CrossRefPubMed
3.
Expert-Bezancon A, Sureau A, Durosay P, Salesse R, Groeneveld H, Lecaer JP, Marie J (2004) hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of beta-tropomyosin exon 6B. J Biol Chem 279:38249–38259CrossRefPubMed
4.
5.
Huang Y, Gattoni R, Stevenin J, Steitz JA (2003) SR splicing factors serve as adapter proteins for TAP-dependent mRNA export. Mol Cell 11:837–843CrossRefPubMed
6.
Huang Y, Yario TA, Steitz JA (2004) A molecular link between SR protein dephosphorylation and mRNA export. Proc Natl Acad Sci USA 101:9666–9670CrossRefPubMed
7.
8.
Jacquenet S, Decimo D, Muriaux D, Darlix JL (2005) Dual effect of the SR proteins ASF/SF2, SC35 and 9G8 on HIV-1 RNA splicing and virion production. Retrovirology 2:33CrossRefPubMed
9.
Lai MC, Tarn WY (2004) Hypophosphorylated ASF/SF2 binds TAP and is present in messenger ribonucleoproteins. J Biol Chem 279:31745–31749CrossRefPubMed
10.
Lemaire R, Prasad J, Kashima T, Gustafson J, Manley JL, Lafyatis R (2002) Stability of a PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: a novel function for SR proteins. Genes Dev 16:594–607CrossRefPubMed
11.
Nishimori H, Shiratsuchi T, Urano T, Kimura Y, Kiyono K, Tatsumi K, Yoshida S, Ono M, Kuwano M, Nakamura Y, Tokino T (1997) A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15:2145–2150CrossRefPubMed
12.
Paca-Uccaralertkun S, Damgaard CK, Auewarakul P, Thitithanyanont A, Suphaphiphat P, Essex M, Kjems J, Lee TH (2006) The effect of a single nucleotide substitution in the splicing silencer in the tat/rev intron on HIV type 1 envelope expression. AIDS Res Hum Retroviruses 22:76–82CrossRefPubMed
13.
Rodgers JT, Patel P, Hennes JL, Bolognia SL, Mascotti DP (2000) Use of biotin-labeled nucleic acids for protein purification and agarose-based chemiluminescent electromobility shift assays. Anal Biochem 277:254–259CrossRefPubMed
14.
Saltarelli MJ, Hadziyannis E, Hart CE, Harrison JV, Felber BK, Spira TJ, Pavlakis GN (1996) Analysis of human immunodeficiency virus type 1 mRNA splicing patterns during disease progression in peripheral blood mononuclear cells from infected individuals. AIDS Res Hum Retroviruses 12:1443–1456CrossRefPubMed
15.
Sanford JR, Gray NK, Beckmann K, Caceres JF (2004) A novel role for shuttling SR proteins in mRNA translation. Genes Dev 18:755–768CrossRefPubMed
16.
Sanford JR, Ellis J, Caceres JF (2005) Multiple roles of arginine/serine-rich splicing factors in RNA processing. Biochem Soc Trans 33:443–446CrossRefPubMed
17.
Sanford JR, Ellis JD, Cazalla D, Caceres JF (2005) Reversible phosphorylation differentially affects nuclear and cytoplasmic functions of splicing factor 2/alternative splicing factor. Proc Natl Acad Sci USA 102:15042–15047CrossRefPubMed
18.
Suptawiwat O, Sutthent R, Lee TH, Auewarakul P (2003) Intragenic HIV-1 env sequences that enhance gag expression. Virology 309:1–9CrossRefPubMed
19.
Suptawiwat O, Lee TH, Auewarakul P (2005) HIV-1 Cis Enhancing Sequence (CES) enhances CTE-dependent Gag expression. Virology 342:111–118CrossRefPubMed
20.
Swartz JE, Bor YC, Misawa Y, Rekosh D, Hammarskjold ML (2007) The shuttling SR protein 9G8 plays a role in translation of unspliced mRNA containing a constitutive transport element. J Biol Chem 282:19844–19853CrossRefPubMed
21.
Takeb EY, Kusagawa S, Motomura K (2004) Molecular epidemiology of HIV: tracking AIDS pandemic. Pediatr Int 46:236–244CrossRef
22.
Tange TO, Damgaard CK, Guth S, Valcarcel J, Kjems J (2001) The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element. EMBO J 20:5748–5758CrossRefPubMed
23.
Xiao SH, Manley JL (1998) Phosphorylation-dephosphorylation differentially affects activities of splicing factor ASF/SF2. EMBO J 17:6359–6367CrossRefPubMed
24.
Zahler AM, Damgaard CK, Kjems J, Caputi M (2004) SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing. J Biol Chem 279:10077–10084CrossRefPubMed
25.
Zhu J, Mayeda A, Krainer AR (2001) Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol Cell 8:1351–1361CrossRefPubMed
Metadata
Title
A novel SR protein binding site in a cis-regulatory element of HIV-1
Authors
Ornpreya Suptawiwat
Chompunuch Boonarkart
Prasert Auewarakul
Publication date
01-11-2010
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 11/2010
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-010-0765-2

Other articles of this Issue 11/2010

Archives of Virology 11/2010 Go to the issue

Original Article

The effect of human immunodeficiency virus type 1 (HIV-1) gp41 variability on antibody detection

Original Article

Two novel mastreviruses from chickpea (Cicer arietinum) in Australia

Brief Report

The complete genome sequence of a virus associated with cotton blue disease, cotton leafroll dwarf virus, confirms that it is a new member of the genus Polerovirus

Brief Report

Interleukin-10 gene polymorphisms in association with susceptibility to chronic hepatitis C virus infection: a meta-analysis study

Annotated Sequence Record

Complete nucleotide sequences of a distinct bipartite begomovirus, bitter gourd yellow vein virus, infecting Momordica charantia

Brief Report

A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits